Search research articles
Contact Us
Filters
Showing results (61-70 of 69) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 69 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 7, 2022
A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006)
Janos L Tanyi, Leslie M Randall, Setsuko K Chambers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2010
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer
Setsuko K Chambers, Mary C Clouser, Amanda F Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2011
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer
Beth Y Karlan, Amit M Oza, Gary E Richardson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 16, 2024
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy
Christof Vulsteke, Setsuko K Chambers, Maria Jesús Rubio Pérez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2018
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Amanda N Fader, Dana M Roque, Eric Siegel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2021
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study
Kathleen N Moore, Setsuko K Chambers, Erika P Hamilton, et al.
Cancer Discovery
|
November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K Lin, Maria I Harrell, Amit M Oza, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 4, 2023
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer
Robert W Holloway, Premal Thaker, Alberto A Mendivil, et al.
Nature Communications
|
May 4, 2021
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 69) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 69 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 7, 2022
A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006)
Janos L Tanyi, Leslie M Randall, Setsuko K Chambers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2010
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer
Setsuko K Chambers, Mary C Clouser, Amanda F Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2011
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer
Beth Y Karlan, Amit M Oza, Gary E Richardson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 16, 2024
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy
Christof Vulsteke, Setsuko K Chambers, Maria Jesús Rubio Pérez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2018
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Amanda N Fader, Dana M Roque, Eric Siegel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2021
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study
Kathleen N Moore, Setsuko K Chambers, Erika P Hamilton, et al.
Cancer Discovery
|
November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K Lin, Maria I Harrell, Amit M Oza, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 4, 2023
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer
Robert W Holloway, Premal Thaker, Alberto A Mendivil, et al.
Nature Communications
|
May 4, 2021
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, et al.
Page
of 7